GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Quick Ratio

Allena Pharmaceuticals (Allena Pharmaceuticals) Quick Ratio : 1.58 (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Allena Pharmaceuticals's quick ratio for the quarter that ended in Jun. 2022 was 1.58.

Allena Pharmaceuticals has a quick ratio of 1.58. It generally indicates good short-term financial strength.

The historical rank and industry rank for Allena Pharmaceuticals's Quick Ratio or its related term are showing as below:

ALNAQ's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.53
* Ranked among companies with meaningful Quick Ratio only.

Allena Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Allena Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals Quick Ratio Chart

Allena Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Quick Ratio
Get a 7-Day Free Trial 12.73 11.19 3.03 6.08 2.11

Allena Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 5.47 2.11 2.00 1.58

Competitive Comparison of Allena Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Allena Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allena Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's Quick Ratio falls into.



Allena Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Allena Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(33.006-0)/15.679
=2.11

Allena Pharmaceuticals's Quick Ratio for the quarter that ended in Jun. 2022 is calculated as

Quick Ratio (Q: Jun. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(16.486-0)/10.425
=1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allena Pharmaceuticals  (OTCPK:ALNAQ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Allena Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
Louis Md Brenner officer: See Remarks RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick director 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz officer: Chief Financial Officer 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan officer: Chief Financial Officer C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p. 10 percent owner C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp 10 percent owner 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper director, 10 percent owner 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin director, officer: Chief Executive Officer C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139

Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines

From GuruFocus